Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190561 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT06190561 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 40 participants.
The verdict
NCT06190561, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-07940367 once by mouth. The participants may receive different tablets by mouth for PF-07940367. The study will compare experiences of people receiving two different products of PF-07940367. This will help understand how much PF-07940367 is taken up into the blood for each product given. Participants will take part in the study for about 112 days. During this time, participants will have to stay onsite for 5 days. There will be up to 2 additional onsite study visits and 3 remote (telephone call) study visits.
Interventions
- DRUG PF-07940367
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06190561
The ClinicalTrials.gov registry entry for NCT06190561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-07940367 is the first listed.
NCT06190561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06190561 about?
NCT06190561 is a clinical study titled "A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults". The purpose of this study is to compare two finished products of PF-07940367 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-07940367 once by mou...
What is the current status of trial NCT06190561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-01-15. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT06190561?
The interventions under investigation include: PF-07940367 (DRUG).
Who is sponsoring clinical trial NCT06190561?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.